Mutual of America Capital Management LLC Has $5.34 Million Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Mutual of America Capital Management LLC decreased its position in Omnicell, Inc. (NASDAQ:OMCL) by 0.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 119,857 shares of the company’s stock after selling 311 shares during the period. Mutual of America Capital Management LLC’s holdings in Omnicell were worth $5,336,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Van ECK Associates Corp grew its holdings in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares during the period. First Horizon Advisors Inc. grew its holdings in shares of Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares during the period. KBC Group NV grew its holdings in shares of Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after buying an additional 778 shares during the period. CIBC Asset Management Inc acquired a new position in shares of Omnicell in the 4th quarter valued at $201,000. Finally, Summit Global Investments acquired a new position in shares of Omnicell in the 3rd quarter valued at $221,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Trading Down 0.9 %

Shares of NASDAQ:OMCL opened at $37.73 on Tuesday. The company’s 50-day moving average price is $42.26 and its two-hundred day moving average price is $43.79. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.74. The stock has a market capitalization of $1.75 billion, a PE ratio of 139.75, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Bank of America reduced their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. JPMorgan Chase & Co. upped their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Finally, Benchmark reaffirmed a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $52.33.

Insiders Place Their Bets

In other news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.64% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.